Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” according to a spokesperson for the pharma.

Then, a company named Regeneron announced they would buy the company, and would “prioritize [consumer data's] privacy, security and ethical use." Now there's been another twist: That company was outbid just before the sale closed,